[August 19, 2014] |
|
Ocular Therapeutix Announces Exercise of Over-Allotment Option
BEDFORD, Mass. --(Business Wire)--
Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused
on the development and commercialization of innovative therapies for
diseases and conditions of the eye, announced today that the
underwriters of its initial public offering have exercised in full their
over-allotment option to purchase an additional 750,000 shares at the
initial public offering price of $13.00 per share, less underwriting
discounts. After giving effect to the over-allotment closing, the total
number of shares sold by Ocular Therapeutix in its initial public
offering increased to 5,750,000 shares, which resulted in gross proceeds
of approximately $74.8 million and net proceeds of approximately $66.5
million after deducting underwriting discounts and estimated offering
expenses.
Morgan Stanley, Cowen and Company and RBC Capital Markets acted as joint
book-running managers for the offering. Oppenhimer & Co. acted as a
co-manager. A copy of the final prospectus relating to the offering may
be obtained from Morgan Stanley & Co. LLC, attention: Prospectus
Department, 180 Varick Street, 2nd Floor, New York, New York 10014;
Cowen and Company, LLC, c/o Broadridge Financial Services, attention:
Prospectus Department, 1155 Long Island Avenue, Edgewood, NY, 11717; or
RBC Capital Markets, LLC, attention: Equity Syndicate, Three World
Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281-8098.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on July 24, 2014.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities, in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix's lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma, ocular hypertension and
allergic conjunctivitis. The Company is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.
[ Back To TMCnet.com's Homepage ]
|